Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
3 American Growth Giants to Invest in for the Long Haul
07:30am, Friday, 30'th May 2025
Many of the best growth stocks in the world are based out of the U.S. This is the land of both opportunity and innovation. Warren Buffett has always been bullish on betting on the U.S. because he's a
Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions
05:00pm, Thursday, 29'th May 2025
INDIANAPOLIS , May 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of orforglipron, insulin efsitora alfa, tirzepatide (Zepbound and Mounjaro), ret
PFE or LLY: Which Is the Better Value Stock Right Now?
12:46pm, Thursday, 29'th May 2025
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Pfizer (PFE) or Eli Lilly (LLY). But which of these two stocks presents investors with the better val
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
07:35am, Thursday, 29'th May 2025
Eli Lilly NYSE: LLY has transformed from a steady pharmaceutical giant into one of Wall Street's standout growth stories—and it's not just hype. Powered by blockbuster drugs for diabetes and weight
Novo Nordisk's weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly's Zepbound, and now the company is trying to get back on track.
Eli Lilly to Expand Pain Pipeline With $1B SiteOne Buyout Offer
12:31pm, Wednesday, 28'th May 2025
LLY inks $1B deal to acquire SiteOne, adding phase II-ready pain drug STC-004 to strengthen its neuroscience pipeline.
Eli Lilly vs. AstraZeneca: Which Pharma Powerhouse is the Better Buy?
10:25am, Wednesday, 28'th May 2025
Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.
Eli Lilly expands neuroscience pipeline with $1B acquisition of SiteOne therapeutics
03:46pm, Tuesday, 27'th May 2025
Eli Lilly and Co (NYSE:LLY) announced it is acquiring SiteOne Therapeutics, a private biotech firm developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitab
Breaking The Pain Barrier: Lilly's Acquisition Of SiteOne Aims For Opioid Alternatives
03:32pm, Tuesday, 27'th May 2025
Eli Lilly And Co LLY on Tuesday agreed to acquire SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal h
Eli Lilly to acquire privately held SiteOne
10:09am, Tuesday, 27'th May 2025
Eli Lilly will acquire privately held SiteOne Therapeutics, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain drug.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
10:05am, Tuesday, 27'th May 2025
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
10:00am, Tuesday, 27'th May 2025
Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS , May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and SiteOne Therapeutics, In
Here's How the Pharmaceutical Import Tariffs Could Affect Eli Lilly
04:44am, Tuesday, 27'th May 2025
Eli Lilly's (LLY -0.12%) share price soared during the first Trump administration. That momentum continued with Joe Biden in the White House.
Prediction: These 2 Stocks Will Beat the Market in the Next Decade
03:46am, Tuesday, 27'th May 2025
Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies.
Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
05:05pm, Thursday, 22'nd May 2025
INDIANAPOLIS , May 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD
